[Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].
In 61 out-patients with essential hypertension, grade I or II, propranolol was administered alone in increasing doses (3 x 40 mg/d or 3 x 80 mg/d) or, if there was insufficient response, with a double or triple combination consisting additionally of spironolactone (50 mg/d)-thiabutazide (5 mg/d) and dihydralazine (3 x 25 mg/d). This treatment schedule achieved normal pressures in 51 patients, in 22 on 40 mg, in 7 on 80 mg propranolol, in 16 after the addition of the diuretic, and in 6 with the triple combination. Four patients had to be excluded from the study because they developed either marked bradycardia or anxiety states or paraesthesias after propranolol (3 x 40 mg/d). On chronic beta-adrenergic blockade the serum potassium level increased slightly, but remained within normal limits. The initial value of plasma-renin activity was highest in the group of those who responded to the propranolol treatment.
D001007:Anxiety; D001919:Bradycardia / Q000139:chemically induced; D004078:Dihydralazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D006852:Hydrochlorothiazide / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D010292:Paresthesia / Q000139:chemically induced; D011188:Potassium / Q000097:blood; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*
D006852:Hydrochlorothiazide; D006830:Hydralazine; D013148:Spironolactone; D011433:Propranolol; D012083:Renin; D004078:Dihydralazine; D011188:Potassium
Kombinationsbehandlung der essentiellen Hypertonie mit Propranolol, Spironolacton-Thiabutazid und Dihydralazin.